Celldex Therapeutics (CLDX) Total Non-Current Liabilities (2010 - 2026)
Celldex Therapeutics (CLDX) posted quarterly Total Non-Current Liabilities of $51.9 million for Q1 2026, up 52.93% year-over-year from $33.9 million in Q1 2025, and little changed quarter-over-quarter from $51.8 million in Q4 2025.
Celldex Therapeutics (CLDX) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Celldex Therapeutics' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $51.9 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 52.93% year-over-year to $51.9 million; the TTM figure through Mar 2026 stood at $51.9 million (up 52.93% YoY), while the FY2025 annual figure was $51.8 million, up 23.68% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $51.9 million, roughly flat from $51.8 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $51.9 million in Q1 2026, with the low at $15.4 million in Q1 2022.
- The 5-year median for Total Non-Current Liabilities is $32.1 million (2023), against an average of $31.4 million.
- The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities jumped 104.19% in 2022, then sank 46.61% in 2023.
- Celldex Therapeutics' Total Non-Current Liabilities stood at $21.2 million in 2022, then surged by 51.21% to $32.1 million in 2023, then jumped by 30.6% to $41.9 million in 2024, then grew by 23.68% to $51.8 million in 2025, then increased by 0.27% to $51.9 million in 2026.
- Business Quant data shows CLDX's Total Non-Current Liabilities at $51.9 million in Q1 2026, $51.8 million in Q4 2025, and $47.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn | 64.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 64.67 Mn |
| Mar 31, 2026 | 51.92 Mn |
| Dec 31, 2025 | 51.78 Mn |
| Sep 30, 2025 | 47.53 Mn |
| Jun 30, 2025 | 34.46 Mn |
| Mar 31, 2025 | 33.95 Mn |
| Dec 31, 2024 | 41.86 Mn |
| Sep 30, 2024 | 33.80 Mn |
| Jun 30, 2024 | 28.45 Mn |
| Mar 31, 2024 | 26.76 Mn |
| Dec 31, 2023 | 32.05 Mn |
| Sep 30, 2023 | 29.14 Mn |
| Jun 30, 2023 | 17.37 Mn |
| Mar 31, 2023 | 17.38 Mn |
| Dec 31, 2022 | 21.20 Mn |
| Sep 30, 2022 | 18.48 Mn |
| Jun 30, 2022 | 32.54 Mn |
| Mar 31, 2022 | 15.40 Mn |
| Dec 31, 2021 | 17.82 Mn |
| Sep 30, 2021 | 15.89 Mn |